PE Deals

Gurnet Point and Novo Holdings to acquire Paratek Pharmaceuticals for $462m

Oaktree Capital Management will provide $175 million in debt financing for this deal.

-
  • When the deal closes, Paratek will stop trading on the NASDAQ
  • The transaction is expected to close in the third quarter of 2023
  • Moelis & Company LLC acted as financial advisor to Paratek Pharmaceuticals while Lazard acted as financial advisor to Gurnet Point Capital

Gurnet Point Capital and Novo Holdings have agreed to take Boston-based Paratek Pharmaceuticals, a biopharmaceutical company, private for about $462 million.

Share this